Assoc Prof of Clin Pediatrics
M_PEDS-HEMATOLOGY
4155021994
Dr. Winger’s research is focused on advancing precision medicine to improve therapeutics and outcomes for patients with cancer and other blood diseases. Her research has two main focuses: 1) understanding mutations in kinases so that we can expand the use of targeted therapies and match the right drug to the right patient, and 2) developing precision dosing strategies to give every patient the right amount of drug for their body.
Publications
Alpelisib, a PI3Kα inhibitor, effectively treats vascular anomalies with diverse genotypes and phenotypes.
Blood vessels, thrombosis & hemostasis
Prediction of neutrophil nadir and recovery following paediatric haematopoietic cell transplantation with busulfan conditioning.
British journal of clinical pharmacology
Younger Children with Non-Malignant Disease Have Increased Incidence of Mixed Myeloid Chimerism After Allogeneic Hematopoietic Cell Transplantation with Busulfan-Based Conditioning.
Transplantation and cellular therapy
Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies.
Pediatric blood & cancer
Effective Use of ALK Inhibitors in EML4::ALK-Positive Lymphatic Malformations.
Pediatric blood & cancer
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research
EML4::ALK fusions in complex lymphatic malformations.
Pediatric blood & cancer
Correction to "Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations".
Journal of chemical theory and computation
Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations.
Journal of chemical theory and computation
Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
Journal of chromatography open
Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
Journal of clinical pharmacology
A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults.
Frontiers in pediatrics
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.
Cancer discovery
The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders.
Transplantation and cellular therapy
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population.
Frontiers in pharmacology
Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.
Journal of clinical pharmacology
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Cancer research
Mycobacterium bovis Enterocolitis in an Immunocompromised Host.
Journal of pediatric gastroenterology and nutrition
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
PLoS biology
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
Nature chemical biology
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.
Cancer cell
Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei.
Chemical biology & drug design